 ATLANTA, GA, March 04, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. GOVX, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for preventioncontrol of novel coronavirus disease COVID-19 caused by SARS-Cov-2 coronavirus. The update was given by GeoVaxs Chief Scientific Officer, Farshad Guirakhoo, PhD, during his presentation on emerging infectious diseases entitled Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform at the World Immunotherapy Congress in San Diego, California. 